Nutritional and botanical modulation of the inflammatory cascade - Eicosanoids, cyclooxygenases, and lipoxygenases - As an adjunct in cancer therapy

Integrative Cancer Therapies

Volumn 1, Issue 1, 2002, Pages 7-37

  Wallace, Jeanne M ^a  

^a Nutritional Solutions Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; BAICALEIN; BOSWELLIC ACID; BROMELAIN; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EPIGALLOCATECHIN GALLATE; FISH OIL; GINSENG EXTRACT; ICOSANOID; INDOMETACIN; INTERLEUKIN 6; LIPOXYGENASE INHIBITOR; METHOTREXATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLANT EXTRACT; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; QUERCETIN; RETINOL; ROFECOXIB; SILYBUM MARIANUM EXTRACT; SULINDAC; UNINDEXED DRUG; VEGETABLE OIL; ZILEUTON;

ANGIOGENESIS; ANIMAL MODEL; BLADDER CANCER; BONE MARROW TOXICITY; BOSWELLIA; BRAIN TUMOR; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CELL CYCLE; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM ULCER; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEVER; GLIOBLASTOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HERBAL MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; INFLAMMATION; KIDNEY FAILURE; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MORTALITY; MOUSE; MOUTH ULCER; NAUSEA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; RAT; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYCLOOXYGENASE INHIBITORS; EICOSANOIDS; HUMANS; INFLAMMATION; LIPOXYGENASE INHIBITORS; NEOPLASMS; NUTRITION THERAPY; SIGNAL TRANSDUCTION;

EID: 0042825578     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735402001001002     Document Type: Review

References (364)

1. Boik J. Natural Compounds in Cancer Therapy. Princeton, MN: Oregon Medical Press; 2001.
2. Fischer S, Slaga T. Arachidonic Acid Metabolism and Tumor Promotion. Boston, MA: Martinus Nijhoff; 1985.
3. Sharma S, Sharma SC. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems. Indian J Exp Biol. 1997;35:1025-1031.
4. Stein-Werblowsky R. Prostaglandins and cancer. Oncology. 1974;30:169-176.
5. Karmali RA. Review: prostaglandins and cancer. Prostaglandins Med. 1980;5(1):11-28.
6. Giovannucci E, Egan KM, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609-614.
7. Langman M, Boyle P. Chemoprevention of colorectal cancer. Gut. 1998;43:578-585.
8. SmalIey W, Ray WA, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999;159:161-166.
9. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am. 1996;125:338-348.
10. Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol. 1998;13:591-597.
11. Tangrea JA, Albert PS, et al. Non-steroidal anti-inflammatory drug use is associated with reduced risk of colorectal adenomas. Proc Am Assoc Cancer Res. 2001;42:177.
12. Kawamori T, Rao CA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409-412.
13. Hara A, Yoshimi N, Niwa M, et al. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res. 1997;88:600-604.
14. Fukutake M, Nakatsugi S, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2 on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis. 1998;19:1939-1942.
15. Yoshimi N, Shimizu M, et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res. 1999;90:406-412.
16. Williams CS, Luongo C, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 1996;111:1134-1140.
17. Taketo MM. COX-2 and colon cancer. Inflamm Res. 1998;47(suppl 2):8112-8116.
18. Oshima M, Dinchuk JE, et al. Suppression of intestinal polyposis in Apc 716 delta knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803-809.
19. Steinbach G, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N Engl J Med. 2000;842:1946-1952.
20. Gottlieb S. COX 2 inhibitors might be useful in cancer prevention. Br J Med. 1999;319:1155.
21. Hao X, Bishop AE, Wallace M, et al. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol. 2000;187:295-301.
22. Sheng H, Shao J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997;99:2254-2259.
23. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518-523.
24. Shiff JS, Koutsos MI, Qiao L, Rigas B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res. 1996;222:179-188.
25. Crew TE, Elder DJ, Paraskeva C. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis. 2000;21(1):69-77.
26. Masunaga R, Kohno H, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064-4068.
27. Sheehan KM, Sheehan K, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999;282:1254-1257.
28. Tomozawa S, Tsuno NH, et al. Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer. 2000;83:324-328.
29. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60:4926-4931.
30. Tatsuhiro J, et al. Differential expression of cyclooxygenase-2 (COX-2) in human gliomas and growth inhibition of glioma cell lines by COX-2 inhibitor in a three-dimensional culture system. Proc Am Assoc Cancer Res. 2000;42:515. Abstract No. 2773.
31. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61:4375-4381.
32. Petersen C, Petersen S, et al. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res. 2000;6:2513-2520.
33. Harris RE, Kasbari S, Farrar WB. Prospective study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;117:71-73.
34. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology. 1996;17:203-205.
35. Gilhooly EM, Rose DP. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol. 1999;15:267-270.
36. Hwang D, Scollard D, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90:455-460.
37. Harris RE, Alshafie GA, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res. 2000;60:2101-2103.
38. Blumenthal RD, Waskewich C, et al. In vitro chemosensitivity and in vivo chronotherapy and chronotoxicity of the COX-2 inhibitor, celecoxib. Proc Am Assoc Cancer Res. 2001;42:926.
39. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep. 2000;7:1377-1381.
40. Fischer SM, Lo HH, et al. The effects of NSAIDs on breast cancer prognostic factors. Oncol Rep. 1999;25:433-435.
41. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56:5125-5127.
42. Kundu N, Yang Q, Dorsey A, Fulton AM. Increased cyclooxygenase-2 (COX-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer. 2001;93:681-686.
43. Badawi AF, Archer MC. Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands. Prostaglandins Other Lipid Mediators. 1998;56(2-3):167-181.
44. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996;137:5739-5742.
45. Koki AT, Harmon J, Woerner M, et al. Characterization of cyclooxygenase-2 (COX-2) expression and Her2/neu in human breast, colon, and prostate cancer. Paper presented at: Annual Meeting of the American Association for Cancer Research; March 28, 2001; New Orleans, LA.
46. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 1999;18:305-314.
47. Mann M, Sheng H, Shao J, et al. Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterol. 2001;120:1713-1719.
48. Sawaoka H, Kawano S, et al. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol. 1998;27(suppl 1):S47-S52.
49. Kang JH, Hong YS, et al. Evaluation of COX-2 expression in human gastric tumors and COX-2 suppression by aspirin and SC0236 in human gastric cancer cells in vitro. Proc Am Assoc Cancer Res. 2001;42(89):17.
50. Ratnasinghe D, Tangrea JA, Roth MJ, et al. Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus. Oncol Rep. 1999;79:965-968.
51. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer. 2001;91:1876-1881.
52. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519-525.
53. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000;6:135-138.
54. Chen CN, Sung CT, Lin MT, et al. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg. 2001;233:183-188.
55. Sales KJ, Katz AA, Davis M, et al. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab. 2001;86:2243-2249.
56. Kulkarni S, Rader JS, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 2001;7:429-434.
57. Comerci JT, Sloan C, et al. Cyclooxygenase-2 expression in normal endometrium, endometrial hyperplasia, and carcinoma. Proc Am Assoc Cancer Res. 2001;42(90):17.
58. Ryu HS, Chang KH, Yang HW, et al. High cyclooxygenase-2 expression in stage 1B cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol. 2000;76:320-325.
59. Gaffney DK, Holden J, et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49:1213-1217.
60. Mestre JR, Chan G, et al. Inhibition of cyclooxygenase-2 expression: an approach to preventing head and neck cancer. Ann NY Acad Sci. 1999;889:62-71.
61. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3(1):53-61.
62. Nishimura C, Yanoma S, et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res. 1999;90:1152-1162.
63. Sumitani K, Kamijo R, Toyoshima T, et al. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med. 2001;30(1):41-47.
64. Hosomi Y, Yokose T, et al. Increased cyclooxygenase-2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000;30(2):73-81.
65. Oatkins DN, Lenzo JC, et al. Expression and localization of cyclooxygenase isoforms in non-small cell lung cancer. Eur Respir J. 1999;14:412-418.
66. Ochiai M, Oguri T, et al. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res. 1999;90:1338-1343.
67. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1589-1594.
68. Hida T, Kozaki K, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 2000;6:2006-2011.
69. Achiwa H, et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 1999;5:1001-1005.
70. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990.
71. Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26(2):69-76.
72. Okami J, Yamamoto H, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer. Res. 1999;5:2018-2024.
73. ip-Schneider MT, Barnard DS, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-146.
74. Kokawa A, Knodo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-338.
75. Fischer SM, Lo HH, et al. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): resutls of a case-control study. Oncol Rep. 2000;25:169-170.
76. Hughes-Fulford M, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis. 2001;22:701-707.
77. Tjandrawinata RR, Hughes-Fulford M. Up-regulation of cyclooxygenase-2 by product - prostaglandin E2. Adv Exp Med Biol. 1997;407:163-170.
78. Subbarayan V, Sabichi AL, et al. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res. 2001;61:2720-2726.
79. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;163(3 pt 1):820-825.
80. Gupta S, Srivastava M, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42(1):73-78.
81. Irani J, Goujon JM, Ragni E, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urol. 1999;54:467-472.
82. Khan KN, Knapp DW, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res. 2000;61:478-481.
83. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional call carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res. 2000;6:2424-2430.
84. Ristimaki A, Nieminen O, Saukkonen K, et al. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol. 2001;158:849-853.
85. Okajima E, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res. 1998;58:3028-3031.
86. Kitayama W, Denda A, et al. Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis. 1999;20:2305-2310.
87. Ziegler J. Early trials probe COX-2 inhibitors' cancer-fighting potential. J Natl Cancer Int. 1999;91:1186-1187.
88. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30(1):3-21.
89. Tjandrawinata RR, Dahiya A, Hughes-Fulford M. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostate carcinoma calls. Br J Cancer. 1997;75:1111-1118.
90. Dempke W, Rie C, Grothey A, Schmoll HD. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127:411-417.
91. Zhang X, Morham SG, et al. Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice. Exp Cell Res. 2000;254:232-240.
92. Bortuzzo C, Hanif R, et al. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta. 1996;I300:240-246.
93. Qiao L, Kozoni V, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta. 1995;2358:215-223.
94. Eli Y, Przedecki F, Levin G, et al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001;61:565-571.
95. Shiff SJ, Qiao L, et al. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induced apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995;96:491-503.
96. Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA. 2000;97:11280-11285.
97. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors: a new class of antiangiogenic agents. Ann NY Acad Sci. 1999;889:84-86.
98. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59:991-994.
99. Marrogi AJ, Travis WD, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res. 2000;6:4739-4744.
100. Sawaoka H, Tsuji S, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79:1469-1477.
101. Masferrar JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311.
102. Jones MK, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-1423.
103. Yamada M, Kawai M, et al. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res. 1999;19:300-304.
104. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19(1-2):19-27.
105. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7:1163-1170.
106. Majima M, Isono M, Ikeda Y, et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn J Pharmacol. 1997;75:105-114.
107. Cheng T, Cao W, et al. Prostaglandin E2 induces vascular endothalial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci. 1998;39:581-591.
108. Hoper MM, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol. 1997;17:748-756.
109. Bamba H, Ota S, et al. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 calls. Biochem Biophys Res Commun. 2000;273:485-491.
110. Williams CS, Watson AJ, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000;60:6045-6051.
111. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000;60:4629-4637.
112. Chen WS, Wei SJ, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2 selective inhibitor, etodolac. Int J Cancer. 2001;91:894-899.
113. Nagatsuka I, Yamada N, et al. Inhibitory effect of COX-2 inhibitor JTE-522 on hepatic metastasis of colon cancer. Proc Am Assoc Cancer Res. 2001;42(4972):926.
114. Tomozawa S, Nagawa H, Tsuno N, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer. 1999;81:1274-1279.
115. Carroll KK. Dietary fats and cancer 1-3. Am J Clin Nutr. 1991;53:S1064-S1067.
116. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol. 1999;94:451-455.
117. Young MR. Eicosanoids and the immunology of cancer. Cancer Metastasis Rev. 1994;13(3-4):337-348.
118. Waymack PJ, Chance WT. Effect of prostaglandin E in multiple experimental models: V: effect on tumor/host interaction. J Surg Oncol. 1990;45:110-116.
119. Huang M, Stolina M, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998;58:1208-1216.
120. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000;164:361-370.
121. Barone J, Hebert JR. Dietary fat and natural killer cell activity. Med Hypothesis. 1988;25:223-226.
122. Baxevanis CN, Reclos GJ, Gritzapis AD, et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer. 1993;72:491-501.
123. Cifone MG, Botti D, Festuccia C, et al. Involvement of phospholipase A2 activation and arachidonic acid metabolism in the cytotoxic functions of rat NK-cells. Cell Immunol. 1993;148:247-258.
124. Matsui Y, Fujikawa K, Oka H, et al. Management of renal cell carcinoma with inferior vena cava tumor thrombus. Urol Int. 2001;66(1):4-8.
125. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 1999;5:4005-4012.
126. Kishi K, Petersen S, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000;60:1326-1331.
127. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to gamma radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst. 1999;91:1501-1504.
128. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multi- forme xenografts. Clin Cancer Res. 2000;6:971-978.
129. Roller A, Bahr OR, Streffer J, et al. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun. 1999;259:600-605.
130. Singh MS, Shaik M. Potentiation of selective COX-2 inhibitor nimesulide against colon and lung cancer cell lines. Proc Am Assoc Cancer Res. 2001;42(4971):926.
131. Hansten PD, et al, eds. Drug Interactions and Updates Quarterly. Vancouver, WA: Applied Therapeutics; 1993.
132. Levin B, Mocharnuk R. COX-2 inhibitors and cancer chemoprevention. 2000. Center for Biomedical Communication Inc. Available at: www.Medscape.com/Medscape/oncology/TreatmentUpdate/2000/tu10/public/toc-tu10. html.
133. McCarty MF. Current prospects for controlling cancer growth with non-cytotoxic agents - nutrients, phytochemicals herbal extracts, and available drugs. Med Hypothesis. 2001;56:137-154.
134. Bland JE. Nutrition, cytokines and inflammation. In: Nutritional. Improvement of Health Outcomes: The Inflammatory Disorders. Gig Harbor, WA: Health Comm Inc; 1997:109-119. Health Comm Seminar Series.
135. Lord RD, Bralley J. Fatty acid metabolism. In: Pizzorno JE, Murray MT, eds. Textbook of Natural Medicine. New York, NY: Churchill Livingstone; 1999:723-731.
136. Steele VE, Holmes CA, et al. Lipoxygenase inhibitors as potential cancer chemopreventive. Cancer Epidemiol Biomarkers Prev. 1999;8:467-483.
137. Ondrey FG, Juhn SK, Adams GL. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope. 1996;106(2 pt 1):129-134.
138. Rose DP, Connelly JM, et al. Influence of diets containing eicosapentaenoic of docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J Natl Cancer Inst. 1995;87:587-592.
139. Connelly JM, Liu XH, Rose DP. Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr Cancer. 1996;25:231-240.
140. Hussey HJ, Tisdale MJ. Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer. 1994;70(1):6-10.
141. Noguchi M, Earashi M, et al. Effects of eicosapentaenoic and docosahexaenoic acid on cell growth and prostaglandin E and leukotriene B production by human breast cancer cell line (MDA-MB-231). Oncology. 1995;52:458-464.
142. Noguchi M, Rose DP, Earashi M, Miyazaki I. The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma. Oncology. 1995;52:265-271.
143. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA. 1996;93:5241-5246.
144. Brown DM, Phipps RP. Bcl-2 expression inhibits prostaglandin E2-mediated apoptosis in B cell lymphomas. J Immunol. 1996;157:1359-1370.
145. Berdanier CD. CRC Desk Reference for Nutrition. New York, NY: CRC Press; 1998:101.
146. Vincent JE, Vermeer MA, et al. The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat. Biochim Biophys Acta. 1990;1042:255-258.
147. Gati I, Bergstrom M, et al. Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines. Prostaglandins Leukotrienes Essential Fatty Acids. 1990;40:117-124.
148. Gati I, Bergstrom M, Westerberg G. Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma speroids. Eur J Cancer. 1990;26:802-807.
149. Blomgren H, Kling-Andersson G. Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids. Anticancer Res. 1992;12:981-986.
150. Anderson K-M, Seed T, et al. Morphologic changes of apoptosis induced in human chronic myelogenous leukemia "blast" cells by SC41661 A (Searle), a selective inhibitor of 5-lipoxygenase. Scanning Microsc. 1994;8:675-684.
151. Anderson KM, Seed T, et al. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk Res. 1995;19:789-801.
152. Anderson KM, Seed T, et al. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induced apoptosis in U937 and CML cells. Anticancer Res. 1996;16:2589-2599.
153. Snyder DS, Castro R, Desforges JF. Antiproliferative affects of lipoxygenase inhibitors on malignant human hematopoietic cell lines. Exp Hematol. 1989;17(1):6-9.
154. Earashi M, Noguchi M, Tanaka M. In vitro effects of eicosanoid synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 1996;37(1):29-37.
155. Tripathi SC, Vosseller KA, McCormick DL. Arachidonic acid metabolism and cell proliferafion in rat mammary carcinoma cells treated with indomethacin. Biochim Biophys Acta. 1996;1316(1):5-7.
156. Cunningham DC, Harrison LY. Proliferative responses of normal human mammary and MCF-7 breast cancer cells to linoleic acid, conjugated linoleic acid and eicosanoid synthesis inhibitors in culture. Anticancer Res. 1997;17:197-203.
157. Hussey HJ, Tisdale MJ. Inhibition of tumour growth by lipoxygenase inhibitors. Br J Cancer. 1996;74:683-687.
158. Malone JP, Snyderman CH. Arachidonic acid metabolites in saliva of patients with squamous cell carcinoma of the head and neck. Oral Surg Oral Med Oral Pathol. 1994;77:636-640.
159. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun. 1997;235:418-423.
160. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. 1998;95:13182-13187.
161. Myers CE, Ghosh J. Lipoxygenase inhibition in prostate cancer. Eur Urol. 1999;35(5-6):395-398.
162. Ding XZ, Iversen P, et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 1999;261:218-223.
163. Natarajan A, Nadler J. Role of lipoxygenases in breast cancer. Front Biosci. 1998;3:81-88.
164. Gao X, Grignon DJ, et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995;46:227-237.
165. Tang K, Honn KV. 12(S)-HETE in cancer metastasis. Adv Exp Med Biol. 1999;447:181-191.
166. Honn KV, Tang DG, et al. 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev. 1994;13:365-396.
167. Honn KV, Tang DG. Eicosanoid 12 (S)-HETE upregulates endothelial cell alpha V beta 3 integrin expression and promotes tumor cell adhesion to vascular endothelium. Adv Exp Med Biol. 1997;400:B765-B773.
168. Liu B, Timar I, et al. Lipoxygenase metabolites of arachidonate and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regul. 1991;2:1045-1055.
169. Chen YQ, Cuniec ZM, et al. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res. 1994;54:1574-1579.
170. Nie D, Hillman GG, et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res. 1998;58:4047-4051.
171. Connelly JM, Rose DP. Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice. Cancer Lett. 1998;132:107-112.
172. Liu B, Maher RJ, et al. 12(S)-HETE increases the motility of prostate tumor cells through selective activation of PKC alpha. Adv Exp Med Biol. 1997;400:B707-B718.
173. Winer I, Su L, et al. 12-lipoxygenase expression in human pigmented skin neoplasia. Proc Am Assoc Cancer Res. 2001;42(97):18.
174. Dethlefsen SM, Shepro D, D'Amore PA. Arachidonic acid metabolites in bFGF, PDGF- and serum-stimulated vascular cell growth. Exp Cell Res. 1994;212:262-273.
175. Stoltz RA, Abraham NG, Laniado-Schwartzman M. The role of NF-kappaB in the angiogenic response of coronary microvessel endothelial cells. Proc Natl Acad Sci USA. 1996;93:2832-2837.
176. Renard P, Raes M. The proinflammatory transcription factor NFkappaB: a potential target for novel therapeutical strategies. Cell Biol Toxicol 1999;15:341-344.
177. Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol. 1996;102(suppl):3-8.
178. Miller JL. Decisions loom on selective COX-2 inhibitors. Am J Health Sys Pharm. 1999;56:106-107.
179. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431-502.
180. Shureiqi I, Chen D, et al. 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory, drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000;60:6846-6850.
181. Frommel TO, Dyavanapalli M, Oldham T, et al. Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients. Clin Cancer Res. 1997;3:209-213.
182. Cullis P, Hope MJ. Physical properties and functional roles of lipids in membranes. In: Vance DE, Vance JE, eds. Biochemistry of Lipids, Lipoproteins and Membranes. Amsterdam: Elsevier; 1991.
183. Karmali RA, Marsh J, Fuchs C. Effect of omega-3 fatty acids on growth of a rat mammary tumor. J Natl Cancer Inst. 1984;73:457.
184. Janti J. Evening primrose oil in rheumatoid arthritis: changes in serum lipids and fatty acids. Ann Rheum Dis. 1989;48:124-127.
185. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70(3 suppl):S560-S569.
186. Schlomo Y, Carasso RL. Modulation of learning, pain thresholds, and thermoregulation in the rat by preparations of free purified alpha-linolenic and linoleic acids: determination of the optimal w3-to-w6 ratio. Proc Natl Acad Sci. 1993;90:10345-10347.
187. Grimble RF, Tappia PS. Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids. Z Ernahrungswiss. 1998;87 (suppl 1):57-65.
188. Murray MT. Encyclopedia of Nutritional Supplements. Rocklin, CA: Prima Publishing; 1996:252.
189. Medeiros LC, et al. Insulin, but not estrogen, correlated with indexes of desaturase function in obese women. Hormone Metab Res. 1995;27(5):23-28.
190. Arm JP, Thein FC, Lea TH. Leukotrienes, fish oil, and asthma. Allergy Proc. 1994;15:129-134.
191. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71(1 suppl):S343-S348.
192. Obata T, Nagakura T, Masaki T, et al. Eicosapentaenoic acid inhibits prostaglandin D2 generation by inhibiting cyclooxygenase-2 in cultured human mast cells. Clin Exp Allergy. 1999;29:1129-1135.
193. Curtis CL, et al. n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem. 2000;275:721-724.
194. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the post-initiation stage of colon carcinogenesis. Cancer Res. 1997;57:3465-3470.
195. Kobayashi J, Yokoyama S, Katamura S. Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages. Prostaglandins Leukotrienes Essential Fatty Acids. 1995;52: 259-262.
196. Chang WL, Chapkin RS, Lupton JR. Fish oil blocks azoxymethane-induced rat colon tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell proliferation. J Nutr. 1998;128:491-497.
197. Endres S, Von Schacky C. Omega-3 polyunsaturated fatty acids and human cytokine synthesis. Curr Opinions Lipidol. 1996; 7(13):48-52.
198. Connelly JM, Rose DP. Effects of fatty acids on invasion through reconstituted basement membrane ("Matrigel") by a human breast cancer cell line. Cancer Lett. 1993;75:137-142.
199. Maehle L, Eilersten E, et al. Effects of n-3 fatty acids during neoplastic progression and comparison of in vitro and in vivo sensitivity of two human tumour cell lines. Br J Cancer. 1995;71: 691-696.
200. Lai PB, Ross JA, et al. Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vivo. Br J Cancer, 1996;74:1375-1383.
201. Reich R, et al. Eicosapentaenoic acid reduces the invasive and metastatic activities of malignant tumor cells. Biochem Biophys Res Commun. 1989;160:559-564.
202. Burns CP, Petersen ES, North JA, Ingraham LM. Effects of docosahexaenoic acid on rate of differentiation of HL-60 human leukemia. Cancer Res. 1989;49:3252-3258.
203. Kanayasu T, Morita I, et al. Eicosapentaenoic acid inhibits tube formation of vascular endothelial cells in vitro. Lipids. 1991; 26:271-276.
204. Yang SP, Morita I, et al. Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via inhibiting Flk-i receptor expression in bovine carotid artery endothelial cells. J Cell Physiol. 1998;176:342-349.
205. Rose DP, Connelly JM. Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol. 1999;15:1011-1015.
206. Mukutmoni-Norris M, Hubbard NE, Erickson KL. Modulation of murine mammary tumor vasculature by dietary n-3 fatty acids in fish oil. Cancer Lett. 2000;150:101-109.
207. Karmali RA, Reichel P, et al. The effects of dietary omega-3 fatty acids on the DU-145 transplantable human prostatic tumor. Anticancer Res. 1987;7:1173-1179.
208. Gonzalez MJ, Schemmel RA, et al. Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis. 1991; 12:1231-1235.
209. Welsch CW, Oakley CS, et al. Suppression of growth by dietary fish oil of human breast carcinomas maintained in three different strains of immune-deficient mice. Nutr Cancer. 1993;20:119-127.
210. Rose DP, Connelly JM, Coleman M. Effect of omega-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. Clin Cancer Res. 1996;2:1751-1756.
211. Senzaki H, Iwamoto S, et al. Dietary effects of fatty acids on growth and metastasis of KPL-1 human breast cancer cells in vivo and in vitro. Anticancer Res. 1998;18:1621-1627.
212. DeBravo MG, DeAntueno RJ, et al. Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. Lipids. 1991;26:866-870.
213. Maehle L, Lystad E, et al. Growth of human lung adenocarcinoma in nude mice is influenced by various types of dietary fat and vitamin E. Anticancer Res. 1999;19:1649-1655.
214. Sakaguchi M, Rowley S, et al. Reduced tumour growth of the human colonic cancer cell lines COLO320 and HT-29 in vivo by dietary n-3 lipids. Br J Cancer. 1990;62:742-747.
215. Sakaguchi M, et al. Relationship of the tissue and tumor fatty acids to dietary fat in experimental colorectal cancer. Gut. 1989;30:1449.
216. Calder PC, Davis J, et al. Dietary fish oil suppresses human colon tumour growth in athymic mice. Clin Sci (Colch). 1998; 94:303-311.
217. Paulsen JE, Stamm T, Alexander J. A fish oil-derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl esters inhibits the formation and growth of aberrant crypt foci in rat colon. Pharmacol Toxicol. 1998;82(13):28-33.
218. Suzuki I, Ioga M, Ishikawa C, et al. Inhibitory effects of oleic and docosahexaenoic acids on lung metastases by colon carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. Int J Cancer. 1997;73:607-612.
219. Jenski LJ, et al. Omega-3 fatty acid-containing liposomes in cancer therapy. Proc Soc Exp Biol Med. 1995;210:227-233.
220. Barber MD, Ross JA, et al. Fish oil-enriched nutritional supplementation attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr. 1999;129:1120-1125.
221. Wigmore SJ, Ross JA, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer Nutrition. 1996;12:527-530.
222. Barber MD, Ross JA, Fearon KC. The anticachectic effect of fatty acids. Proc Nutr Soc. 1998;57:571-576.
223. Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight loss in patients with pancreatic cancer. Br J Cancer. 1999;81:80-86.
224. Gogos CA, et al. The effect of dietary omega-3 polyunsaturated fatty acids on T-lymphocyte subsets of patients with solid tumors. Cancer Detect Prev. 1995;19:415-417.
225. Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized controlled trial. Cancer. 1998;82: 395-402.
226. Tsai WS, Nagawa H, Muto T. Differential effects of polyunsaturated fatty acids on chemosensitivity of NIH3T3 cells and its transformants. Int J Cancer. 1997;70:357-361.
227. Zijlstra JG, deVries ES, et al. Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and -resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int J Cancer. 1987;40:850-856.
228. Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer. 1993;57:728-733.
229. Kinsella JE, Black JM. Effects of polyusaturated fatty acids on the efficacy of antineoplastic agents toward L5178Y lymphoma cells. Biochem Pharmacol. 1993;45:1881-1887.
230. Horie T, Nakamaru M, Masubuchi Y. Docosahexaenoic acid exhibits a potent protection of small intestine from methotrexateinduced damage in mice. Life Sci. 1998;62:1333-1338.
231. Shao Y, Pardini L, Pardini RS. Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Nutr Cancer. 1997; 28(1):63-73.
232. Hardman WE, Moyer MP, Cameron IL. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF-7 breast carcinoma xenografts and ameliorated intestinal side effects. Br J Cancer. 1999;81:440-448.
233. Germain E, Lavandier F, Chajes V, et al. Dietary n-3 polyunsaturated fatty acids and oxidants increase rat mammary tumor sensitivity to epirubicin without change in cardiac toxicity. Lipids. 1999;34(suppl):S203.
234. Vartak S, Robbins ME, Spector AA. Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced killing. Lipids. 1997;32:283-292.
235. Das UN. Gamma-linolenic acid, arachidonic acid, and eicosapentaenoic acid as potential anticancer drugs. Nutrition. 1990; 6:429-434.
236. Gonzalez MJ, Schemmel RA, Dugan L, et al. Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids. 1993;28:827-832.
237. Gonzalez MJ. Fish oil lipid peroxidation and mammary tumor growth. J Am Coll Nutr. 1995;14:325-335.
238. Boik J. Natural Compounds in Cancer Therapy. Princeton, MN: Oregon Medical Press; 2001.
239. Calviello S, Palozza P, Piccioni E, et al. Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer. 1998;75:699-705.
240. Gramaglia A, Loi GR, Mongioj V, Baronzio GF. Increased surviral in brain metastatic patients treated with stereotactic radiotherapy, omega-three fatty acids and bioflavonoids. Anticancer Res. 1999;19(6C):5583-5586.
241. Bagga D, Capone S, Wang HJ, et al. Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst. 1997;89:1123-1131.
242. Bertram HP, Gostner A, Scheppeach W, et al. Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology. 1993;105: 1317-1322.
243. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res. 1999;5:3942-3947.
244. Bender NK, Kraynak MA, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998;5:257-261.
245. Macrides TA, Treschow AR, et al. The anti-inflammatory effects of omega-3 tetraenoic fatty acids isolated from a lipid extract (Lyprinol®) from the New Zealand green-lipped mussel [abstract]. Presented at: 88th American Oil Chemists Society Annual Meeting; May 1997; Seattle, WA.
246. Whitehouse MW, Macrides TA, et al. Anti-inflammatory activity of a lipid fraction (Lyprinol®) from New Zealand green-lipped mussel. Inflam Pharmacol. 1997;5:237-246.
247. Halpern GM. Antiinflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol®). Townsend Lett Doctors Patients. 2000;202:109-113.
248. McMillan DC, Sattar N, Talwar D, et al. Changes in micronutrient concentrations following anti-inflaminatory treatment in patients with gastrointestinal cancer. Nutrition. 2000;15: 425-428.
249. Chinery R, Beauchamp RD, Shyr Y, et al. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Cancer Res. 1998;58: 2323-2327.
250. Mestre JR, Subbaramaiah K, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res. 1997;57: 2890-2895.
251. Kanekura T, Higashi Y, Kanzaki T. Inhibitory affects of 9-cisretinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX-2) expression and cell growth in human skin squamous carcinoma cells. Cancer Lett. 2000;161:177-183.
252. Traber MG, Packer L. Vitamin E: beyond antioxidant function. Am J Clin Nutr. 1995;62(6 suppl):S1501-S1509.
253. Kamimura M. Antiinflammatory effect of vitamin E. J Vitaminol. 1972;18:204-209.
254. Eskew ML, Zarkower A, Scheuchenzuber WJ, et al. Effects of inadequate vitamin E and/or selenium nutrition on the release of arachidonic acid metabolites in rat alveolar macrophages. Prostaglandins. 1989;38(1):79-89.
255. Chan AC, Tran K, Pyke DD, Powell WS. Effect of dietary vitamin E on the biosynthesis of 5-lipoxygenase products by rat polymorphonuclear leukocytes (PMNL). Biochim Biophys Acta. 1989; 1005:265-269.
256. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Does vitamin E supplementation modulate in vivo arachidonate metabolism in human inflammation? Pharmacol Toxicol. 1987;61:246-249.
257. Upritchard JE, Sutherland WHF, Mann JI. Effect of supplementation with tomato juice, vitamin E and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care. 2000;23:733-738.
258. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. Gamma-tocopherol and its major metabolic, in contrast to alpha tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA. 2000;97:11494-11499.
259. Safayhi H, Mack T, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992;261: 11143-1146.
260. Safayhi H, Sailer ER, et al. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995; 47:1212-1216.
261. Safayhi H, Sailer ER, et al. 5-lipoxygenase inhibition, by acetyl-11-keto-beta-boswellic acid (AKBA) by a novel mechanism. Phytomedicine. 1996;3(1):71-72.
262. Sailer ER, Schweizer S, et al. Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem. 1998;256:364-368.
263. Ammon HP, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med. 1991;57:203-207.
264. Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol. 1993; 38(2-3):113-119.
265. Shao Y, Ho CT, et al. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med. 1998;64:328-331.
266. Jing Y, Nakajo S, et al. Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leuk Res. 1999;23:43-50.
267. Glaser T, Winter S, Groscurth P, et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer. 1998;80(5-6):756-765.
268. Winking M, Sarikaya S, et al. Boswellic acids inhibit glioma growth. J Cancer Res Clin Oncol. 1998;124:8141.
269. Winking M, Sarikaya S, et al. Boswellic acids inhibit glioma growth: a new treatment option? J Neurooncol. 2000;46:97-103.
270. Boeker DK, Winking M. The role of boswellic acids in the therapy of malignant glioma [in German]. Deutsches Aerzteblatt. 1997;94:A1197-A1199.
271. Janssen G, Bode U, Breu H, et al. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr. 2000;212:189-195.
272. Taussig S, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application: an update. J Ethnopharmacol. 1988;22:191-203.
273. Taussig S. The mechanism of the physiological action of bromelain. Med Hypothesis. 1980;6:99-104.
274. Vellini M, et al. Possible involvement of eicosanoids in the pharmacological action of bromelain. Arzneimittelforschung. 1986; 36:110-112.
275. Tassman G, et al. A double-blind crossover study of plant proteolytic enzyme in oral surgery. J Dent Med. 1965;20:51-54.
276. Batkin S, et al. Antimetastatic effect of bromelain with or without its proteolytic and anticoagulant activity. J Cancer Res Clin Oncol. 1988;114:507-508.
277. Batkin S, et al. Modulation of pulmonary metastasis (Lewis lung carcinoma) by bromelain, an extract of the pineapple stem (Ananas comosus) [letter]. Cancer Invest. 1988;6:241-242.
278. Gerard C. Therapeutique anti-cancreuse et bromelaines. Agressologie. 1972;3:261-274.
279. Nieper HA. Bromelain in der kontrolle malignen washtums. Krebsgeschehen. 1976;1:9-15.
280. Eckert K, Grabowska E, et al. Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. Oncol Rep. 1999;6:1191-1199.
281. Felton GE. Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients. Med Hypothesis. 1980;6:1123-1133.
282. Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications. J Am Diet Assoc. 1995;95:580-584.
283. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharm. 1976;25:1811-1812.
284. Toda S, Miyase T, Arichi H, et al. Natural antioxidants: III: antioxidative components isolated from rhizome of Curcuma longa. Chem Pharmacol Bull. 1985;33:1725-1728.
285. Zhang F, et al. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis. 1999;20:445-451.
286. Gupta OP, Sharma N, Chand D. Application of papaya latex-induced rat paw inflammation: model for evaluation of slowly acting antiarthritic drugs. J Pharmacol Toxicol Methods. 1994; 31(2):95-98.
287. Srivastava R, Srimal RC. Modification of certain inflammation-induced biochemical changes by curcumin. Indian J Med Res. 1985;81:215-223.
288. Srivastava R, Mustafa T. Spices, antiplatelet activity and prostanoid metabolism. Prostaglandins Leukotrienes Essential Fatty Acids. 1989;38:255-266.
289. Flynn DL, Rafferty MF, Boctor AM. Inhibition of 5-hydroxyeicosatetraenoid acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leukotrienes Med. 1986;22(3):357-360.
290. Huang MT, Lysz T, Ferraro T, et al. Inhibitory activities of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 1991;51:813-819.
291. Joe B, Lokesh BR. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzymes secretion by rat peritoneal macrophages. Lipids. 1997;32:1173-1180.
292. Conney AH, Lou YR, Xie JG, et al. Some perspectives on dietary inhibition of carcinogenesis: studies with curcumin and tea. Proc Soc Exp Biol Med. 1997;216:234-245.
293. Rao CV, et al. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995;55:259-266.
294. Plummer SM, Sharma RA, et al. Curcuminoids inhibit cyclooxygenase-mediated prostaglandin E2 production and COX-2 expression in human blood. Proc Am Assoc Cancer Res. 2001;42(93):17-18.
295. Satoskar RH, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986;24:651-654.
296. Deodhar SD, Sethi R, Srimal RC. Preliminary studies on antirheumatic activity of curcumin (diferuloylmethane). Indian J Med Res. 1980;71:632-634.
297. Mehta K, Pantazis P, McQueen T, Aggarwal BB. Curcumin (diferuloylmethane) is a potent antiproliferative agent against human breast tumor cell lines. Anticancer Drugs. 1997;8:470-481.
298. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer: II: curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol. 2000;4(1):1-6.
299. Chen H, Zhang ZS, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res. 1999;19 (5A):3675-3680.
300. Goel A, et al. Inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Proc Am Assoc Cancer Res. 1999;40:528-529.
301. Elattar TM, Virji AS. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res. 2000;20(3A):1733-1738.
302. Ramsewak RS, De Witt DL, Nair MG. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine. 2000;7:303-308.
303. Kuttan R, et al. Potential anticancer activity of tumeric. Cancer Lett. 1985;29:197-202.
304. Kuo ML, et al. Curcumin, an antioxidant and anti-tumor promoter, induced apoptosis in human leukemia cells. Biochim Biophys Acta. 1996;1317:95-100.
305. Gautam SC, Xu YX, Pindolia KR, et al. Nonselective inhibition of proliferation of transformed and nontransformed cells by the anticancer agent curcumin (diferuloylmethane). Biochem Pharmacol. 1998;55:1333-1337.
306. Moragoda L, Jaszewsky R, Majumdar AP. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 2001;21(2A):873-878.
307. Jee SH, Shen SC, Tseng CR, et al. Curcumin induced a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol. 1998;111:650-661.
308. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer. 1996;26:111-120.
309. Thaloor D, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ. 1998;9:305-312.
310. Singh AK, et al. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett. 1996;107:109-115.
311. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4:376-383.
312. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett. 1995;95(1-2):221-225.
313. Menon LG, Kuttan R, Kuttan G. Anti-metastalic activity of curcumin and catechin. Cancer Lett. 1999;141(1-2):159-165.
314. Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol. 2000;131:169-172.
315. Venkatesan N, Punithavathi D, Chandrakasan C. Curcumin protects bleomycin-induced lung injury in rats. Life Sci. 1997; 61(6):51-58.
316. Venkatesan N, Chandrakasan G. Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant. Mol Cell Biocham. 1995;142(1):79-87.
317. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol. 2000; 129:231-234.
318. Sriganth I, Premalatha B. Dietary curcumin with cisplatin administration modulates tumor marker indices in experimental fibrosarcoma. Pharm Res. 1999;39:175-179.
319. Boik J. Natural Compounds in Cancer Therapy. Princeton, MN: Oregon Medical Press; 2001:280.
320. Kuttan R, et al. Tumeric and curcumin as topical agents in cancer therapy. Tumori. 1987;73(1):29-31.
321. Shankar T, et al. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs and monkeys. Indian J Exp Biol. 1980;18:73-75.
322. McGuffin M, Hobbs C, Upton R, Goldberg A. Botanical Safety Handbook. New York, NY: CRC Press; 1997:39
323. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol. 1983;32:1141-1148.
324. Baumann J, et al. Flavonoids and related compounds as inhibition of arachidonic acid peroxidation. Prostaglandins. 1980; 20:627-639.
325. Welton AF, Hurley J, Will P. Flavonoids and arachidonic acid metabolism. Prog Clin Biol. Res. 1988;280:301-312.
326. Welton AF, Tobias LD, Fiedler-Nagy C, et al. Effect of flavonoids on arachidonic acid metabolism. Prog Clin Biol Res. 1986;213: 231-242.
327. Mutoh M, et al. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis. 2000;21:959-963.
328. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Alternative Med Rev. 2000;5:196-208.
329. Kandaswami C, Perkins E, Drzewiecki G, et al. Differential inhibition of proliferation of human squamous cell carcinoma, gliosarcoma and embryonic fibroblast-like lung cells in culture by plant flavonoids. Anticancer Drugs. 1992;3:525-530.
330. Castillo MH, Perkins E, Campbell JH, et al. The effects of the bioflavonoid quercetin on squamous cell carcinoma of head and neck origin. Am J Surg. 1989;158:351-355.
331. Caltagirone S, Ranelletti FO, Rinelli A, et al. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol. 1997;17(1):51-59.
332. Singhal RL, Yey YA, Praja N, et al. Quercetin down-regulates signal transduction in human breast carcinoma cells. Biochem Biophys Res Commun. 1995;208:425-431.
333. Scambia G, Ranelletti FO, Panici PB, et al. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. Br J Cancer. 1990;62:942-946.
334. Larocca LM, Giustacchini M, Maggiano N, et al. Growth-inhibitory effect of quercetin and presence of type II estrogen binding sites in primary human transitional cell carcinomas. J Urol. 1994;152:1029-1033.
335. Yoshida M, Sakai T, Hosokawa N, et al. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett. 1990;260(1):10-13.
336. Richter M, Eberman R, Marian B. Quercetin-induced apoptosis in colorectal tumor cells: possible role of EGF receptor signalling. Nutr Cancer. 1999;34(1):88-99.
337. Ranelletti FO, Ricci R, Larocca LM, et al. Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors. Int J Cancer. 1992;50:486-492.
338. Vazquez B, Avila G, Segura D, Escalante B. Anti-inflammatory activity of extracts from Aloe vera gel. J Ethnopharmacol. 1996; 55:69-75.
339. Haqqi TM, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA. 1999;96:4524-4529.
340. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 1998;273:21875-21882.
341. Ohuchi K, et al. Glycyrrhizin inhibits prostaglandin E2 formation by activated peritoneal macrophages from rats. Prostaglandin Med. 1981;7:457-463.
342. Dirsch VM, Vollmar AM. Ajoene, a natural product with nonsteroidal anti-inflammatory drug (NSAID)-like properties? Biochem Pharmacol. 2001;61:587-593.
343. VanLoon IM. The golden root: clinical applications of Scutellaria baicalensis GEORGI flavonoids as modulators of the inflammatory response. All Med Rev.
344. Butenko IG, et al. Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis greorgy roots. Agents Actions. 1993: 39(C):49-51.
345. Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7:133-138.
346. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 1999;11(1):80-86.
347. Barber MD, Fearon KC, Ross JA. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci. 1999;96(1):83-87.
348. Kolebacz B. Concentrations of selected acute phase proteins and immunity immunoglobulins in the treatment of head and neck carcinomas [in Polish]. Otalaryngol Pol. 1999;53:743-746.
349. McMillan DC, Wotherspoon HA, Fearon KC, et al. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995;170:319-322.
350. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176: 335-338.
351. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995;75:2077-2082.
352. Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol. 2001;38 (2 suppl 3):21-27.
353. Matsui Y, Fujikawa K, Oka H, et al. Management of renal cell carcinoma with inferior vena cava tumor thrombus. Urol Int. 2001;66(1):4-8.
354. Wigmore SJ, MacMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg. 2001;88:255-260.
355. Nielsen HJ, Christensen IJ, Sorensen S, et al. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal coloi-ectal cancer. Ann Surg Oncol. 2000;7:617-623.
356. O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000;37(1):36-40.
357. McMillan DC, Leen E, Smith J, et al. Effects of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1995;21:531-534.
358. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17:1019-1025.
359. Cengiz M, Akbulut S, Atahan IL, Grigsby PW. Acute phase response during radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49:1093-1096.
360. Hu RJ, Lee PH, Yu SC. Secretion of acute-phase proteins before and after hepatocellular carcinoma resection. J Formos Med Assoc. 1999;98(2):85-91.
361. Goddard DH, Bomalaski JS, et al. Phospholipase A2-mediated inflammation induces regression of malignant glioma. Cancer-Lett. 1996;102(1-2):1-6.
362. Komhoff M, Guan Y, Shappel HW, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol. 2000;157(1):29-35.
363. Scioscia KA, Snyderman CH, et al. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal anti-inflammatory drugs. Am J Otolarygol. 1997;18(1):1-8.
364. Anderson KM, Seed T, et al. 5-lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate. 1998;37:161-173.